secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001193125-25-035787
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis
--------------------------------------------------------------------------------

- Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.
- Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.
- Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.
- 51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.
- MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/0001193125-25-035787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-035787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer